

Review

Not peer-reviewed version

---

# Can Disruption of Circadian Rhythms Be Linked to Radiation-Induced Acute Myeloid Leukaemia?

---

[Aleksandra Czyzak](#) , [Grainne O'Brien](#) , Milagrosa Lopez Riego , [Lourdes Cruz-Garcia](#) , [Christophe Badie](#) \*

Posted Date: 21 May 2026

doi: 10.20944/preprints202605.1402.v1

Keywords: acute myeloid leukaemia; clock genes; circadian rhythms disruption; ionizing radiation; DNA damage response; shift-work; ATM; p53; PER1/2/3



Preprints.org is a free multidisciplinary platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC, OpenAlex.

Copyright: This open access article is published under a [Creative Commons CC BY 4.0 license](#), which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Disclaimer/Publisher's Note: The statements, opinions, and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions, or products referred to in the content.

Review

# Can Disruption of Circadian Rhythms Be Linked to Radiation-Induced Acute Myeloid Leukaemia?

Aleksandra Czyzak <sup>1,2</sup>, Grainne O'Brien <sup>1</sup>, Milagrosa Lopez Riego <sup>1</sup>, Lourdes Cruz-Garcia <sup>1</sup> and Christophe Badie <sup>1,\*</sup>

<sup>1</sup> UK Health Security Agency, RCCE, Radiation Effects Department, Chilton, Didcot, Oxfordshire, OX11 0RQ, United Kingdom

<sup>2</sup> University of Oxford, Department of Oncology, Oxford, Oxfordshire, OX4 1ET, United Kingdom

\* Correspondence: christophe.badie@ukhsa.gov.uk

## Simple Summary

Acute myeloid leukaemia (AML) is a rapidly progressing blood cancer with poor survival rates, particularly in adults over 60 years old. Exposure to ionizing radiation (IR) can contribute to AML development, while modern shift work patterns that disrupt the body's natural daily rhythms may increase cancer risk. Clock Genes (CGs) help regulate critical processes, including DNA repair and blood cell production. When these rhythms are disrupted, through nightshift work or irregular sleep, the body's ability to repair damaged DNA may be compromised. This review examines how radiation exposure, in the context of disrupted circadian rhythm, might lead to AML development. Understanding these connections could help identify at-risk populations, and potentially lead to better treatment timing strategies and improved shift workplace health policies.

## Abstract

Acute myeloid leukaemia (AML) remains a highly lethal malignancy with poor prognosis in adults above 60 years old, and often occurs after radiation exposure. Emerging evidence suggests that circadian rhythm disruption, prevalent in shift workers, may contribute to cancer development. Clock Genes (CGs) regulate fundamental cellular processes, including the DNA damage response (DDR), cell cycle progression, and haematopoiesis. This review examines the pathways linking circadian clock dysregulation to radiation-induced AML (rAML) and evaluates how temporal disruption may modulate leukemogenesis and radiation-induced effects. The evidence was synthesised on core clock components (*BMAL1*, *CLOCK*, *PER*, *CRY*, *REV-ERB*, *ROR*), their dysregulation in AML, and their roles in radiation response. Epigenetic and post-transcriptional regulatory mechanisms, including m<sup>6</sup>A RNA modification and sirtuin-mediated chromatin remodelling, were evaluated for their contribution to circadian-regulated DNA repair capacity. Multiple CGs demonstrated aberrant expression in AML, with *BMAL1* showing tissue-specific dysregulation and *PER1/2/3* consistently downregulated in peripheral blood. Clock proteins directly regulate DNA damage checkpoints through interactions with ATM/CHK2 and p53 pathways. Circadian disruption enhances inflammatory signalling, promotes accumulation of myeloid-derived suppressor cells, and accelerates immune senescence. Moreover, radiation exposure modulates CGs expression, which may alter repair fidelity and increase the leukemogenic risk. Understanding these connections in the context of disrupted circadian rhythm, could help identify at-risk populations, and improve shift workplace health policies.

**Keywords:** acute myeloid leukaemia; clock genes; circadian rhythms disruption; ionizing radiation; DNA damage response; shift-work; ATM; p53; *PER1/2/3*

## 1. Introduction

Acute myeloid leukaemia (AML) is a rapidly progressing haematological group of malignancies characterised by the clonal expansion of immature haemopoietic stem cells (HSCs) in the bone marrow [1]. Clonal expansion occurs at the expense of normal daughter cell production, such as red blood cells, platelets, and white blood cells. The onset of AML symptoms typically occurs within a few weeks. It is characterised by nonspecific symptoms, such as fatigue and shortness of breath, recurrent infections, and a tendency to bruise and bleed due to bone marrow failure [2].

150,000 new cases of AML are diagnosed worldwide each year, making it the most common form of acute leukaemia in adults [3]. Despite advances in traditional therapies (radiotherapy, chemotherapy, bone marrow transplantation, or targeted therapies) the prognosis remains poor, with overall five-year survival rates for those over 60 years old receiving intensive treatment at 20%, and only 2% of the population surviving a year without any treatment [4]. The multifactorial nature of AML pathogenesis involves acquired somatic mutations and environmental exposures such as ionizing radiation (IR) [5]. IR can act as a cancer initiator, promoter, or accelerator, depending on various factors, including the latency period to diagnosis, radiation quality, dose, dose rate, route of exposure, and the sensitivity, kinetics, and organisational structure of cells within the target tissue or organ. Additional factors, such as sex, age at exposure, and hormonal levels, may also influence the risk of developing radiation-induced AML (rAML) [6]. rAML demonstrates the leukemogenic potential of IR. Historically, rAML cases were reported following atomic bomb exposures and nuclear accidents (Hiroshima, Nagasaki or Chernobyl) [7,8]. Nowadays, rAML occurs more frequently as secondary malignancies in patients treated with radiotherapy [9].

Modern lifestyle patterns associated with industrialised societies have introduced circadian rhythm disruption as a relevant oncogenic factor [10]. Chronic misalignment between endogenous circadian clocks and environmental or social timing, as occurs in night-shift workers, individuals exposed to artificial light at night, or those with irregular sleep schedules, disrupts this temporal organisation. In 2007, the International Agency for Research on Cancer (IARC) listed shift work that involves circadian disruption as a probable human carcinogen, based on sufficient evidence from animal studies and limited evidence from human epidemiological research [11]. Shift work is prevalent in the modern world, with 19% of people in Europe working night shifts, as reported by the Sixth European Working Conditions Survey, and so the long-term health implications of these individuals are of particular concern [12].

However, evidence of shiftwork as a carcinogen in humans has been inconsistent. A large review on 12 studies investigated the increased risk of prostate cancer in night workers [13] and found conflicting results, with some studies reporting an increased risk, up to 3-fold [14] while other studies reported no increased risk of prostate cancer [15]. Interestingly, where no increased risk was reported, the authors observed an association among men who had worked night shifts for more than 28 years. Previous studies investigating the link between shift work and haematological cancers have been mostly inconclusive, but a recent large-scale study involving over 70,000 nurses reported an increased risk of several types of hematopoietic cancers, again with a longer duration of night-shift work of over 15 years [16]. The inconsistency in reported cancer risk could be due to issues such as a lack of clarity in the definition of night shift work, different populations studied, and different cancer outcomes, such as incidence or mortality, reported [13]. A recent systematic review screened over 500 studies and found strong evidence supporting associations between circadian disruption and breast, prostate, and colorectal cancers, and, to a lesser extent, melanoma and bladder cancers [17].

It is suggested that night-shift schedules can desynchronise and blunt peripheral clock gene (PCG) expression, while appropriately timed bright light can acutely realign these molecular rhythms [18]. A study on healthy adults exposed to a 4-day simulated night shift (10-h sleep delay) with a dense 24-h time-series sampling of peripheral blood mononuclear cells (PBMCs) for circadian transcriptome profiling found loss of circadian coordination and disruption of NK cell-mediated immunity as well as *JUN/AP-1* and *STAT* signalling, suggesting plausible immune-stress mechanisms that may link night shift work to adverse health effects [19]. Desynchrony was also

shown in central markers (melatonin and cortisol) and distinct PBMC expression; however, *PER1* rhythms in PBMCs appeared similarly phased, suggesting downstream transcriptomic reorganisation rather than a uniform shift of core clock genes (CGs) [20]. Emerging evidence points to a direct role of CGs dysregulation in haematological malignancies [21,22]. Studies have shown that components of the core clock, including *BMAL1*, *CLOCK*, *PER*, and *CRY* gene families, intersect with cell cycle checkpoints, DNA damage responses, and apoptotic signalling [23]. Perturbations in these genes alter HSC homeostasis and promote malignant transformation [24].

This review examines the mechanistic pathways through which circadian clocks regulate DNA repair response, haematopoiesis, and leukemogenesis. It synthesises evidence linking circadian disruption with radiation-induced damage, highlights alterations of specific CGs in AML, and discusses emerging translational opportunities in chronoradiotherapy and occupational health. The goal is to outline how circadian biology can inform both cancer prevention and therapeutic optimization in AML, shaping future diagnostic, regulatory, and treatment pathways.

## 2. Acute Myeloid Leukaemia and Radiation

The high heterogeneity of AML has been recognised since the early analysis of AML karyotypes [25]. Currently, the World Health Organisation [26] identifies 25 subtypes of AML. The mutational landscape of AML frequently includes recurrent alterations in genes regulating transcription (*RUNX1*, *CEBPA*), signalling (*FLT3*, *KIT*), and epigenetic machinery (*DNMT3A*, *TET2*, *IDH1/2*), highlighting the disease's heterogeneous origins. While these somatic events underpin leukemogenesis, environmental and therapeutic exposures, particularly IR, serve as extrinsic contributors [27].

The leukemogenicity potential of IR depends on multiple parameters, including dose, dose rate, radiation quality, and fractionation schedule [28]. A persistent challenge in understanding rAML is defining the initiating cellular and molecular events. DNA lesions, such as point mutations, small insertions or deletions, and translocations, are primary drivers of cancer. However, the presence of such mutations does not invariably result in malignancy, indicating that additional promoting factors are required for clonal outgrowth [29]. This "multi-hit" model suggests that IR is one of several cooperating events that contribute to complete leukemic transformation [30]. Disruption of circadian rhythms may serve as one such cofactor; therefore, it is essential to investigate how dysregulation of circadian rhythms may modify AML risk.

## 3. Clock Genes, DNA Integrity, and Cell Cycle Regulation


Circadian clocks are molecular timekeeping systems that synchronise physiological processes with environmental cycles [31]. At the cellular level, circadian rhythms are generated through transcriptional–translational feedback loops (TTFLs) composed of core CGs and proteins, including *CLOCK*, *BMAL1*, *PER*, *CRY*, *REV-ERBs*, *RORs*, and *CK1 $\epsilon$*  [32]. In the primary loop, heterodimers of *CLOCK* and *BMAL1* bind to E-box promoter elements to activate transcription of *PER* and *CRY* genes. The translated proteins accumulate, are phosphorylated by *CK1 $\epsilon$* , and re-enter the nucleus to inhibit *CLOCK*–*BMAL1* activity, thereby closing the negative feedback loop. Auxiliary loops, mediated by *REV-ERB $\alpha/\beta$*  and *ROR $\alpha/\beta/\gamma$* , regulate *BMAL1* transcription and stabilize oscillations. Additional repressors such as DEC proteins and co-factors, including *NPAS2*, *NCORs*, and *PPARs*, introduce further complexity [33]. These clock-controlled networks extend beyond rhythmic gene expression to intersect with the cell cycle and DNA integrity checkpoints.

Studies in mammalian tissues reveal temporal gating of cell cycle transitions, DNA synthesis, and mitosis, with clock proteins directly regulating checkpoint regulators. For instance, *CLOCK*–*BMAL1* complexes drive *c-MYC* transcription during the G0/G1 transition, coupling growth signalling to circadian time [34]. Conversely, *BMAL1* suppresses p21, a cyclin-dependent kinase inhibitor; loss of *BMAL1* leads to elevated p21 and altered G1/S progression. At the G2/M checkpoint, *BMAL1* and *CLOCK* regulate the expression of *Wee1* kinase, which inhibits *CDK1* and delays mitotic

entry [34]. Knockdown of *CLOCK* or *BMAL1* reduces Cyclin B1 levels, impairing checkpoint fidelity [35]. These findings demonstrate that circadian clocks do not merely track time but actively gate cell proliferation (Figure 1).

A central mechanism linking circadian clocks to genome maintenance is the DNA damage response (DDR). *PER1* has been shown to associate with the ATM–CHK2 complex, a sensor-effector pathway activated by IR-induced double-strand breaks. Through this interaction, *PER1* enhances checkpoint activation, promoting either DNA repair or apoptosis [36]. *NPAS2* has been implicated in maintaining genomic stability by regulating DDR-related gene expression, while *CRY* proteins influence ATR/CHK1-mediated responses to replication stress [37]. Together, these interactions indicate that circadian clocks establish a temporal architecture of DNA repair capacity, modulating cellular outcomes following genotoxic stress.

The oncological implications of circadian–cell cycle crosstalk are supported by evidence from cancer models. Screens in mice reveal the heterodimeric circadian rhythm TFs *Clock* and *Bmal1* as genes required for the growth of AML cells in vitro and in vivo [23].



**Figure 1. Circadian clock regulation of the cell cycle and DNA damage response.** Mammalian cell cycle phases (G<sub>1</sub>, S, G<sub>2</sub>, M) and key checkpoint controls, highlighting interactions with circadian clock components. Core clock proteins *BMAL1* and *CLOCK* influence cell cycle progression via C-Myc and p21 regulation at the G<sub>1</sub>/S and M/G<sub>1</sub> checkpoints. *PER1* and *ATM* cooperate with *CHK2* to regulate the G<sub>2</sub>/M checkpoint. *TIM* and *CRY2* modulate the S phase checkpoint via *ATR* and *CHK1* signalling. *Cyclin B1/CDK1* and its regulation by *CDC25* and *Wee1*, with modulation by *BMAL1* and *CLOCK*. Modified from Farshadi, van der Horst, and Chavex (2020). Created in BioRender. O'Brien, G. (2026) <https://BioRender.com/ark4bxa>.


#### 4. Circadian Control of Haematopoiesis

Haematopoiesis is a tightly regulated process that ensures the continuous renewal of blood and immune cells from multipotent HSCs [38]. This process follows circadian oscillations that synchronise cell proliferation, differentiation, and mobilisation with the body's systemic physiological needs [39]. Early research showed rhythmic variations in bone marrow engraftment and mitotic activity, indicating the presence of intrinsic oscillators within the haematopoietic niche. Later studies confirmed that circadian rhythms regulate HSC trafficking, with peak egress into the bloodstream occurring during the organism's rest phase in both rodents and humans [22]. CGs such

as *Per1*, *Per2*, *Bmal1*, and *Clock* demonstrate circadian expression patterns in murine bone marrow, and approximately 6–9% of the human blood transcriptome fluctuates rhythmically across the day–night cycle [40]. Circadian control extends beyond HSC trafficking to influence lineage commitment and immune cell function [41]. For example, rhythmic regulation of cell cycle genes coordinates progenitor proliferation, while oscillations in cytokine production and receptor expression modulate immune readiness. These rhythms ensure that haematopoietic and immune responses are optimally timed to predictable environmental stressors such as pathogen exposure during the active phase [42]. Disruption of circadian clocks, whether by genetic manipulation or environmental perturbation, disturbs these dynamics and impairs immune competence [43]. Studies of CGs knockouts underscore the functional relevance of circadian regulation in haematopoiesis. Mice deficient in *Bmal1* exhibit premature ageing phenotypes, shortened lifespan, and impaired HSC self-renewal, reflecting the role of circadian oscillators in sustaining stem cell homeostasis [33]. Circadian regulation of haematopoiesis provides critical insight into radiation sensitivity. HSCs cycling in and out of quiescence have similar radiosensitivity but are thought to use different DNA repair mechanisms. If circadian rhythms are altered, this serves as another point to be explored in tumorigenesis [44].

## 5. Clock Gene Dysregulation in AML and Radiation Response

Dysregulation of CGs has been documented across multiple malignancies, including haematological cancers [45]. In AML, these genes represent both mechanistic drivers of leukemogenesis and potential biomarkers for disease stratification and prognosis. The specific patterns of circadian gene dysregulation in AML reveal a complex network of alterations that may contribute to disease pathogenesis and alter DNA damage repair mechanisms (Figure 2).



**Figure 2. Circadian clock gene transcriptional dysregulation in the peripheral blood of AML patients.** Colours indicate direction of reported change of CGs expression (red increase; blue decrease) in AML relative to normal conditions, represented by the arrow. Studies have shown that *CLOCK* and *BMAL1* are downregulated or silenced in leukaemic cells, with a 5-fold decrease of *BMAL1* when compared with healthy individuals. *PER1/2/3* and *CRY1/2* are downregulated in human studies and upregulated in AML remission. Increased blast cells in bone marrow correlated with decreased expression of *PER1* and *PER3*. *TIM* is downregulated in AML and upregulated in remission. Interestingly, *BMAL1* expression was found to be significantly upregulated in bone marrow samples from human AML patients in comparison to healthy donors. Upregulated *CK1s* promote *PER*

turnover, facilitating cyclin accumulation and cell cycle progression. *RORα* has been overexpressed in AML cells, and *RORγ* was upregulated in a study of volunteers with AML, as an essential factor for the Th17 cell lineage. *SHARP1* is upregulated in MLL-AF6 AML. \**BMAL1* expression in bone marrow. Created in BioRender. Lopez Riego, M. (2026) <https://BioRender.com/hcrij6e>.

### 5.1. Clock Genes in AML

#### 5.1.1. BMAL1 and CLOCK

*Clock* and *Bmal1* play an important role in cellular proliferation and cell-cycle progression in AML cells. In a recent study using a murine model of AML, it was shown that the genes *Bmal1* and *Clock* regulate the expression of leukaemic stem cells, with disruption of the circadian pathway producing anti-leukaemic effects such as impaired differentiation and depletion of leukaemia stem cells (LSCs) [23]. *BMAL1* expression was found to be significantly upregulated in bone marrow samples from human AML patients in comparison to healthy donors [46]. The level of *BMAL1* expression was found to correlate with cytogenetics with high *BMAL1* expression associated with poor survival.

Interestingly, in peripheral blood, the opposite was found. Human studies reported transcriptional silencing of the CpG island promoter of *BMAL1* in AML in 19% of studied patients [47]. Transcriptional analysis of the peripheral blood of newly diagnosed AML patients found *BMAL1* expression was significantly down-regulated by 5-fold compared with healthy individuals along with downregulation of *PER1*, *PER2*, *PER3*, *CRY1*, *CRY2* and *CLOCK* [48]. Another study showed that *BMAL1* was the most down-regulated gene among *CRY1*, *CRY2*, *CLOCK*, *PER2*, and *REV-ERBα* in PBMPBMCs from AML patients [49].

#### 5.1.2. NPAS2

As a paralog of *CLOCK*, *NPAS2* forms heterodimers with *BMAL1* and compensates for *CLOCK* in regulating E-box-driven transcription [32]. *NPAS2* was found to be upregulated in AML patients (Figure 2), indicating that the knockdown in AML cells leads to cell cycle arrest at G1 and G2 and apoptosis [50].

#### 5.1.3. PERs and CRYs

*PER1* and *PER2* are widely considered tumour suppressors. In the peripheral blood of AML patients, the expression of *PER1*, *PER2*, *PER3*, *CRY1*, and *CRY2* has been found downregulated [48]. Increased blast cells in bone marrow correlated with decreased expression of *PER1* and *PER3*. Moreover, *PER1* and *PER3* expression were significantly upregulated in patients who achieved remission but remained low in those whose disease relapsed. *Per1* and *Cry1* were also suggested to be directly controlled by the *Clock* and *Bmal1* complex and to be mediators in *Clock* and *Bmal1* activity in AML [23]. Overexpression of *Per2* in haematopoietic cancer cell lines resulted in growth inhibition, cell cycle arrest, apoptosis, and loss of clonogenic abilities [51]. In acute promyelocytic leukaemia, caused by the fusion of the *PML* gene and the retinoic acid receptor alpha gene, it has been demonstrated that *PLM* physically interacts with *PER2* and that *PLM* is regulated by *PER2*; however, the specific mechanisms are still unclear [52] (Figure 2).

#### 5.1.4. TIM

*TIM* facilitates the activation of ATR/CHK1 and ATM/CHK2 in DDR [53]. In the peripheral blood of AML patients, *TIM* was shown to be downregulated compared with healthy individuals and upregulated in patients who achieved remission [48].

### 5.1.5. CK1 $\epsilon$

*CK1 $\epsilon$*  appears to be significantly upregulated in the peripheral blood of AML patients. Functionally, *CK1 $\epsilon$*  promotes proteasomal degradation of PER proteins; its upregulation in AML accelerates PER turnover, facilitating cyclin accumulation and cell cycle progression [54].

### 5.1.6. REV-ERBs and RORs


*REV-ERB $\alpha/\beta$*  (*NR1D1/2*) and *ROR $\alpha/\beta/\gamma$*  (*RORA/B/C*) form an auxiliary circadian loop that fine-tunes *BMAL1* transcription: REV-ERBs repress *BMAL1* by recruiting NCOR–HDAC3 co-repressor complexes, whereas RORs activate *BMAL1* via RORE elements. In AML, *REV-ERB $\alpha$*  was found to be downregulated [51]. In contrast, *ROR $\gamma$*  was upregulated in a study of volunteers with AML [55]. This opens a new opportunity to investigate ROR levels in night-shift workers.

### 5.1.7. Other Regulators

*SHARP1*, a suppressor of *CLOCK* and *BMAL1*, is upregulated in MLL-AF6 AML, while *REV-ERB $\alpha$*  and *PPAR $\alpha$* , which normally repress *BMAL1* or modulate metabolic clocks, are often reduced, suggesting altered circadian–metabolic crosstalk [56]. Co-repressors *NCOR1/2* are recruited by AML fusion proteins (e.g., AML1/ETO), enforcing chromatin compaction around differentiation genes [57].

## 5.2. Role of Circadian Genes in DNA Damage Response

It has been established that CGs play a key role in cell cycle regulation. This regulation also extends to the DNA damage response pathway (Figure 3A). As previously discussed, *BMAL1* suppresses *p21* and regulates *Wee1* and *Cyclin B*. Further roles of *BMAL1* in the DDR have also been established with *BMAL1* capable of directly binding to the *p53* gene promoter region, activating the DDR pathway in a *p53*-dependent manner [58]. Also, a ChIP assay in mouse blood samples showed that *Bmal1* protein binds directly to the *Atm* promoter region [59]. *PER2* interacts directly with *p53*, protecting it from MDM2-mediated ubiquitination and degradation, thereby stabilising *p53* activity and enhancing transcription of pro-arrest genes such as *p21* [60]. *BMAL1* further indirectly regulates this pathway through its repression of its downstream *PER1/PER2* [61]. *Per3* depleted HeLa cells resulted in impaired *Chk2* activation, while overexpression of *Per3* lead to increased phosphorylation of *Chk2* and activation of the ATM-Chk2 pathway [62]. Polymorphisms of the genes *PER3* [63] and *NPAS2* have also been associated with cancer risk [64].



**Figure 3. Mapping the influence of ionizing radiation on core circadian clock genes and DNA-damage responses with potential relevance to radiation-induced acute myeloid leukaemia (rAML).** (a) Role of the circadian genes *BMAL1*, *PER1*, *PER2* and *PER3* in the DNA damage response and influence of *PER3* and NPAS2 SNPs on cancer incidence. (b) Colours indicate direction of reported change of *PER1*, *BMAL1*, *PER2* transcriptional changes and ATM, CHK2, P53 protein levels (red increase; blue decrease) after circadian dysregulation and circadian dysregulation combined with IR exposure. This leads to outcomes which could contribute to the development of AML. Created in BioRender. O'Brien, G. (2026) <https://BioRender.com/k7zxc4c>.

### 5.3. Clock Genes After Irradiation

#### 5.3.1. BMAL1 After Irradiation

Only a limited number of studies have investigated the expression of CGs after IR exposure, and none have examined the link to AML development to our knowledge. Nonetheless, *BMAL1* expression is positively correlated with increased radiosensitivity in nasopharyngeal carcinoma and keratinocytes [65]. After irradiation in the heart, *Bmal1* protein levels were inversely associated with DNA damage levels, and *Bmal1* depletion increased IR-induced DNA damage and apoptosis, suggesting that *Bmal1* might protect against IR-induced toxicities [59]. In adrenocortical carcinoma cells, *BMAL1* depletion significantly enhanced the sensitivity of cells to DNA damage-based therapies [66].

#### 5.3.2. NPAS2 Expression in DNA Damage Response

NPAS2 was found to enhance the stability of H2AX mRNA and to decrease tumour cell sensitivity by augmenting DDR. Evidence from breast cancer models and non-Hodgkin's lymphoma shows that NPAS2 loss impairs DDR and reduces DNA repair capacity, underscoring its role in genomic stability [37]. Whether similar regulation occurs in AML remains to be determined.

#### 5.3.3. PERs and CRYs After Irradiation

In human cancer cells, *PER1* overexpression results in increased DNA damage-induced apoptosis [67]. In glioma tissue, high expression of *PER1* and *PER2* is associated with increased sensitivity to X-ray irradiation. Enhanced expression might improve the efficacy of radiotherapy against glioma by promoting apoptosis [68,69]. *CRY1*, upregulated by IR-induced DNA damage, modulates the expression of homologous recombination repair genes, and is regarded as a pro-tumorigenic factor [70].

#### 5.3.4. REV-ERBs and RORs After Irradiation

Direct studies examining how REV-ERB or ROR signalling modulates irradiation responses in AML or normal haematopoietic cells remain limited. IR was found to reduce the mRNA expression of all three RORs [71]. Preliminary data showed that ROR $\alpha$  antagonist SR1001 and Rev-Erb $\alpha$  agonist GSK4112 significantly enhanced radiation-induced type I IFN activation [72].

## 6. Epigenetic and RNA-based Modulators

Circadian regulation is not limited to transcriptional–translational feedback loops of core CGs but extends into broader epigenetic and post-transcriptional layers of gene regulation. Epigenetic modifiers and RNA-modifying enzymes cooperate with circadian proteins to fine-tune gene expression, chromatin accessibility, and state-dependent impact on IR-induced damage and DNA repair [73]. Here, we explore the additional concepts that might link AML, CGs and IR in a broader epigenetic perspective.

### 6.1. m<sup>6</sup>A RNA Modification

Circadian clocks interact with RNA methylation pathways. One of the most prominent RNA modifications, N<sup>6</sup>-methyladenosine (m<sup>6</sup>A), dynamically regulates mRNA stability, splicing, and translation. The methyltransferase METTL3, in complex with METTL14, functions as a key writer of m<sup>6</sup>A marks, while demethylases such as FTO and ALKBH5 act as erasers. A third group of proteins, known as readers, regulate m<sup>6</sup>A metabolism by determining the downstream effects of m<sup>6</sup>A modifications such as YTHDF2, YTHDF1, YTHDF3, YTHDC1, YTHDC2, IGF2BP1/2/3 and members of the HNRNP family. BMAL1 was shown to regulate rhythmic expression of m<sup>6</sup>A regulators, while methylation itself can confer temporal control on RNA stability and translation efficiency in hepatic lipid metabolism [74]. Ck1δ is regulated by m<sup>6</sup>A and when m<sup>6</sup>A is inhibited, the expression of Ck1δ isoforms increases. This increase slows the clock by increasing phosphorylation of PER2 at a key residue, stabilising the PER2 protein [75].

In AML, METTL3/METTL14 is consistently upregulated and promotes leukemic cell self-renewal by enhancing translation of oncogenic transcripts, including c-MYC, BCL2, and PTEN [76]. FTO supports leukemogenesis by demethylating pro-apoptotic transcripts, suppressing cell death and maintaining stemness. Pharmacological inhibition of FTO with FB23-2, reduces AML cell viability and enhances differentiation, demonstrating therapeutic potential [77]. ALKBH5 has been shown to be overexpressed in AML, and its increased expression correlates with poor prognosis in AML patients, particularly in t(8;21) AML [78].

In the context of radiation exposure, m<sup>6</sup>A levels are rapidly and transiently altered within minutes of exposure [79], with site-specific changes that may regulate the stability and turnover of stress-responsive transcripts during early radiation response. γ-Irradiation (4 Gy) in mouse bone marrow provokes rapid, reversible remodelling of the m<sup>6</sup>A epitranscriptome and transcriptome, with a characteristic 5-min increase and 2-h decrease in m<sup>6</sup>A fold-enrichment and mRNA abundance, and early enrichment of coding-sequence peaks [80,81].

### 6.2. Sirtuins and Chromatin Regulation

Sirtuins are NAD<sup>+</sup>-dependent histone deacetylases that integrate circadian metabolic cues with epigenetic programming. SIRT1 deacetylates both BMAL1 and PER2, shaping circadian oscillations of transcription [82]. In AML cells, SIRT1 and SIRT2 are frequently overexpressed, promoting leukemic cell survival under stress by enhancing DNA repair and maintaining redox balance [83,84]. SIRT2 inhibition induces apoptosis in AML cells and sensitises them to chemotherapy, while dual inhibition of sirtuins can disrupt DDR, potentially enhancing radiation sensitivity [83].

## 7. Inflammation as a Link Between AML, DNA Damage Repair and Circadian Rhythm

Inflammation is a hallmark of cancer promoting its progression [85]. Recent literature demonstrates a link between circadian disruption, inflammatory signalling, DNA damage responses and cancer biology. Thus, circadian misalignment induced by night shift work, irregular light exposure or behavioural desynchrony alters transcriptional programmes that govern DNA repair, cell cycle progression and immune surveillance might contribute to AML development [86,87].

### 7.1. Clock Genes Expression, Inflammation and Cancer

Studies suggest that cancer is associated with both immunostimulation and immunosuppression, mediated by increased levels of cytokines such as TNF-α and IL-6, and that systemic therapies, such as radiotherapy, may trigger additional inflammatory responses [87]. The regulation of the inflammatory response may be linked to disrupted CGs; in human glioblastoma, downregulation of BMAL1 and CLOCK induced glioblastoma stem cell cycle arrest and apoptosis, whereas upregulation of CLOCK promoted immune suppression [86]. In breast cancer, high CLOCK

expression correlates with reduced CD8+ T-cell infiltration and increased M2 macrophage polarisation, consistent with increased PD-L1 expression [88].


### 7.2. Circadian Dysregulation, Inflammation and Cancer

Clock disruption has also been shown to drive cancer progression by promoting the accumulation of myeloid-derived suppressor cells (MDSCs) and reducing the proportion of CD8+ cytotoxic T cells [89]. MDSCs are present at very low numbers in healthy subjects but can expand significantly in malignant, infectious, and chronic inflammatory diseases, including AML, although few studies have examined MDSCs in acute leukaemias [90]. Similarly, simulation of chronic jet lag (advancing the light-dark cycle by 6 h every 2 days) has been suggested to induce widespread reprogramming of immune and metabolic pathways and to alter tissue-level glucose uptake, demonstrating that circadian disruption can reshape oncogenic signalling environments in vivo [91]. Long-term circadian misalignment accelerates immune senescence, increases PD-1-Positive CD44-high T cell populations, and expands germinal centre B cells, indicating that persistent inflammatory activation arises directly from clock disruption and may create a permissive niche for malignant transformation in myeloid progenitors [92]. Night shift work and artificial light at night produce internal desynchrony between central and peripheral oscillators and alter peripheral blood mononuclear cell CG expression, suggesting that the haematopoietic compartment is directly sensitive to environmental timing cues that are frequently disrupted in modern societies [93].

### 7.3. DNA Damage Response, Inflammation and Cancer

Ionizing radiation initiates a tightly interconnected network of DDR and inflammatory signalling which could collectively shape cancer progression and therapeutic outcome. One of the links between DDR, inflammation and cancer could be through the cGAS-STING activation pathway. Unrepaired damaged chromosomes after IR exposure can lead to micronuclei formation and release of nuclear DNA to the cytosol upon micronuclei rupture where it can be detected by cGAS [94]. This converts genotoxic stress into innate immune activation through STING-TBK1-IRF3 signalling, driving type I interferons and pro-inflammatory cytokines [95]. This inflammatory axis enhances dendritic cell priming and cytotoxic T-cell recruitment, providing a mechanistic basis for radiation-induced immunogenicity [96]. Persistent cytosolic DNA and sustained STING activation can promote senescence-associated secretory phenotypes enriched in IL-6, IL-8, CCL2 and related chemokines, fostering immunosuppression, fibrosis and tumour-supportive remodelling. Macrophages exposed to radiation adopt a mixed inflammatory phenotype, secreting IL-6, IL-1 $\beta$ , TNF- $\alpha$  and CCL chemokines that can either support anti-tumour immunity or drive pathological inflammation. High radiation doses also induce TREX1, degrading cytosolic DNA and suppressing cGAS activation, thereby limiting beneficial immune priming while permitting residual inflammatory damage [97]. The cGAS and STING expression has been found to be elevated in AML patients compared to healthy controls with a higher NRAS/KRAS mutation rate and lower complete remission rate [98]. SNPs in the cGAS-STING signalling pathways were also associated with AML and related to AML susceptibility, chemotherapy response and AML overall survival [99]. Interestingly, STING was found to play a vital role in the MSCDs differentiation [100], which in combination with MSCDs caused by the clock gene disruption, could drive cancer progression.

These findings would suggest and support a model in which circadian disruption amplifies inflammatory signalling through cGAS-STING pathway after DDR, thereby creating conditions that may facilitate AML initiation and progression, opening avenues for further exploration (Figure 4).



**Figure 4.** Circadian disruption results in clock gene and cell cycle dysregulation, melatonin suppression, increased inflammation and reduced natural killer activity. This leads to impaired DNA repair, abnormal cell growth, elevated estrogen levels, increased immune response and enhanced immune evasion. The addition of ionizing radiation would also increase activity of the cGAS-STING pathway. All factors could contribute to an increased risk of AML development. Created in BioRender. O'Brien, G. (2026) <https://BioRender.com/suou9w4>.

## 8. Conclusions

Understanding how circadian disruption in the context of ionizing radiation exposure may enhance AML development, remains in its early stages. Evidence from basic research, epidemiology, and preclinical models has established that circadian clocks influence DNA repair, cell cycle control, and haematopoiesis. Several areas stand out as priorities for future research. Firstly, defining how circadian phases alter repair fidelity, checkpoint activation, and apoptotic thresholds in normal and pre-leukemic stem cells will clarify how circadian disruption contributes to leukemogenesis, perhaps through inflammation. Secondly, incorporating circadian assessment into night-shift worker cohorts may uncover associations between circadian misalignment and AML incidence and/or latency. Prospective studies in radiotherapy patients that include monitoring of circadian biomarkers could provide the most substantial evidence. Then, core CGs and epigenetic regulators influenced by circadian timing hold potential as biomarkers for radiation sensitivity. Ultimately, in a broader context, these findings could have a significant impact on occupational and public health strategies. Policies addressing circadian health in radiation-exposed occupational groups, including healthcare workers and nuclear industry employees, may have a long-term preventive impact. If successful, these efforts could yield not only a deeper understanding of AML pathogenesis but also innovative strategies for policy prevention and chronoradiotherapy.

**Funding:** This study is funded by the National Institute for Health and Care Research (NIHR) Health Protection Research Unit in Radiation Threats and Hazards (NIHR207424), a partnership between UK Health Security Agency and Imperial College London. The views expressed are those of the authors and not necessarily those of the NIHR, UK Health Security Agency or the Department of Health and Social Care.

**Conflicts of Interest:** The authors declare no conflicts of interest.

## Abbreviations

The following abbreviations are used in this manuscript:

AML	Acute myeloid leukaemia
CGs	Clock genes
ChIP	Chromatin immunoprecipitation
DDR	DNA damage response
HSCs	Haemopoietic stem cells
IL-6	Interleukin-6
IR	Ionizing radiation
LSCs	Leukaemia stem cells
m <sup>6</sup> A	N <sup>6</sup> -methyladenosine
MDSCs	Myeloid-derived suppressor cells
NAD <sup>+</sup>	Nicotinamide adenine dinucleotide
NK	Natural Killer
PBMCs	Peripheral blood mononuclear cells
PCGs	Peripheral clock genes
PD-1	Programmed cell death protein 1
PD-L1	Programmed death-ligand 1
rAML	Radiation-induced acute myeloid leukaemia
TFS	Transcription factors
TNF- $\alpha$	Tumour necrosis factor alpha
TTFLs	Transcriptional-translational feedback loops

## References

1. Hwang, S.M. Classification of acute myeloid leukemia. *Blood Res.* **2020**, *55*, S1–S5.
2. Khwaja, A.; Bjorkholm, M.; Gale, R.E.; Levine, R.L.; Jordan, C.T.; Ehninger, G.; Bloomfield, C.D.; Estey, E.; Burnett, A.; Cornelissen, J.J.; Scheinberg, D.A.; Bouscary, D.; Linch, D.C. Acute myeloid leukaemia. *Nat. Rev. Dis. Primers* **2016**, *2*, 16010.
3. Shimony, S.; Stahl, M.; Stone, R.M. Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. *Am. J. Hematol.* **2023**, *98*, 502–526.
4. Dharmani, C.; Wang, E.; Tu, N.; Salas, M.; Mostafa Kamel, Y. Characteristics and outcomes of elderly patients with acute myeloid leukaemia who receive no treatment in the Surveillance, Epidemiology and End Results–Medicare database. *Future Oncol.* **2023**, *19*, 159–171.
5. Klymenko, S.V.; Smida, J.; Atkinson, M.J.; Bebeshko, V.G.; Nathrath, M.; Rosemann, M. Allelic imbalances in radiation-associated acute myeloid leukemia. *Genes* **2011**, *2*, 384–402.
6. Butturini, A. and Gale, R.P. How can we cure leukaemia? *Br. J. Haematol.* **1989**, *72*, 479–485.
7. Hsu, W.L.; Preston, D.L.; Soda, M.; Sugiyama, H.; Funamoto, S.; Kodama, K.; Kimura, A.; Kamada, N.; Dohy, H.; Tomonaga, M.; Iwanaga, M.; Miyazaki, Y.; Cullings, H.M.; Suyama, A.; Ozasa, K.; Shore, R.E.; Mabuchi, K. The incidence of leukemia, lymphoma and multiple myeloma among atomic bomb survivors: 1950–2001. *Radiat. Res.* **2013**, *179*, 361–382.
8. Samoylov, A.S.; Bushmanov, A.Y.; Udalov, Y.D.; Galstyan, I.A.; Nugis, V.Y.; Kozlova, M.G.; Nikitina, V.A.; Khvostunov, I.K.; Golub, E.V. Acute myeloid leukemia, prostate and skin cancer

- in acute radiation syndrome survivor after the 1986 Chernobyl nuclear accident: Case report. *Radiat. Prot. Dosimetry* **2018**, *182*, 62–66.
9. Dracham, C.B.; Shankar, A.; Madan, R. Radiation induced secondary malignancies: A review article. *Radiat. Oncol. J.* **2018**, *36*, 85–94.
  10. Song, C.; Zhang, R.; Wang, C.; Fu, R.; Song, W.; Dou, K.; Wang, S. Sleep quality and risk of cancer: Findings from the English longitudinal study of aging. *Sleep* **2021**, *44*.
  11. Straif, K.; Baan, R.; Grosse, Y.; Secretan, B.; El Ghissassi, F.; Bouvard, V.; Altieri, A.; Benbrahim-Tallaa, L.; Cogliano, V. Carcinogenicity of shift-work, painting, and fire-fighting. *Lancet Oncol.* **2007**, *8*, 1065–1066.
  12. Eurofound. *Working Time Patterns for Sustainable Work*; Publications Office of the European Union: Luxembourg, 2017.
  13. Wendeu-Foyet, M.G.; Bayon, V.; Cénée, S.; Trétarre, B.; Rébillard, X.; Cancel-Tassin, G.; et al. Night work and prostate cancer risk: Results from the EPICAP study. *Occup. Environ. Med.* **2018**, *75*, 573–581.
  14. Parent, M.É.; El-Zein, M.; Rousseau, M.C.; Pintos, J.; Siemiatycki, J. Night work and the risk of cancer among men. *Am. J. Epidemiol.* **2012**, *176*, 751–759.
  15. Papantoniou, K.; Castaño-Vinyals, G.; Espinosa, A.; Aragonés, N.; Pérez-Gómez, B.; Burgos, J.; Gómez-Acebo, I.; Llorca, J.; Peiró, R.; Jimenez-Moleón, J.J.; Arredondo, F.; Tardón, A.; Pollán, M.; Kogevinas, M. Night shift work, chronotype and prostate cancer risk in the MCC-Spain case-control study. *Int. J. Cancer* **2015**, *137*, 1147–1157.
  16. Zhang, Y.; Birmann, B.M.; Papantoniou, K.; Zhou, E.S.; Erber, A.C.; Schernhammer, E.S. Rotating nightshift work and hematopoietic cancer risk in US female nurses. *JNCI Cancer Spectr.* **2020**, *4*, 106.
  17. Clemente-Suarez, V.J.; Navarro-Jiménez, E.; Benitez-Agudelo, J.C.; Beltrán-Velasco, A.I.; Belinchón-de-Miguel, P.; Ramos-Campo, D.J.; Villanueva-Tobaldo, C.V.; Martín-Rodríguez, A.; Tornero-Aguilera, J.F. The multifaceted impact of circadian disruption on cancer risk: a systematic review of insights and economic implications. *J. Natl. Cancer Cent.* **2025**, *5*, 524–536.
  18. Cuesta, M.; Boudreau, P.; Dubeau-Laramée, G.; Cermakian, N.; Boivin, D.B. Simulated night shift disrupts circadian rhythms of immune functions in humans. *J. Immunol.* **2016**, *196*, 2466–2475.
  19. Kervezee, L.; Cuesta, M.; Cermakian, N.; Boivin, D.B. Simulated night shift work induces circadian misalignment of the human peripheral blood mononuclear cell transcriptome. *Proc. Natl. Acad. Sci. U.S.A.* **2018**, *115*, 5540–5545.
  20. Resuehr, D.; Wu, G.; Johnson, R.L., Jr.; Young, M.E.; Hogenesch, J.B.; Gamble, K.L. Shift work disrupts circadian regulation of the transcriptome in hospital nurses. *J. Biol. Rhythms* **2019**, *34*, 167–177.
  21. Motiei, M.; Abu-Dawud, R.; Relógio, A.; Assaf, C. Circadian rhythms in haematological malignancies: therapeutic potential and personalised interventions. *EBioMedicine* **2024**, *110*, 105451.
  22. Méndez-Ferrer, S.; Chow, A.; Merad, M.; Frenette, P.S. Circadian rhythms influence hematopoietic stem cells. *Curr. Opin. Hematol.* **2009**, *16*, 235–242.
  23. Puram, R.V.; Kowalczyk, M.S.; De Boer, C.G.; Schneider, R.K.; Miller, P.G.; McConkey, M.; Tothova, Z.; Tejero, H.; Heckl, D.; Järås, M.; Chen, M.C.; Li, H.; Tamayo, A.; Cowley, G.S.; Rozenblatt-Rosen, O.; Al-Shahrour, F.; Regev, A.; Ebert, B.L. Core circadian clock genes regulate leukemia stem cells in AML. *Cell* **2016**, *165*, 303–316.
  24. Ainciburu, M.; Cacciotti, L.; Durán-Lázaro, S.; Giustacchini, A.; Bonadies, N.; Majeti, R. Uncovering perturbations in human haematopoiesis associated with healthy ageing and myeloid malignancies at single-cell resolution. *eLife* **2023**, *12*, 79363.
  25. Kurzer, J.H. and Weinberg, O.K. Updates in molecular genetics of acute myeloid leukemia. *Semin. Diagn. Pathol.* **2023**, *40*, 155–166.

26. College of American Pathologists. What's new in AML classification (WHO 2022 vs International Consensus Classification). Available online: <https://www.cap.org> (accessed on 1 November 2025).
27. Leuraud, K.; Richardson, D.B.; Cardis, E.; Daniels, R.D.; Gillies, M.; O'Hagan, J.A.; Hamra, G.B.; Haylock, R.; Laurier, D.; Moissonnier, M.; Schubauer-Berigan, M.K.; Thierry-Chef, I.; Kesminiene, A. Ionizing radiation and risk of death from leukaemia and lymphoma in radiation-monitored workers (INWORKS): An international cohort study. *Lancet Haematol.* **2015**, *2*, 276–281.
28. Stouten, S.; Verduyn Lunel, S.; Finnon, R.; Badie, C.; Dekkers, F. Modeling low-dose radiation-induced acute myeloid leukemia in male CBA/H mice. *Radiat. Environ. Biophys.* **2021**, *60*, 67–78.
29. Zhou, W. and Zhang, J. Multi-context modeling of driver pathways reveals common and specific mechanisms across 23 cancer types. *PLoS Comput. Biol.* **2025**, *21*, e1013349.
30. Badie, C. and Gale, R.P. What is radiation-induced acute myeloid leukaemia/can it be accurately identified? *Leukemia* **2025**, *39*, 1334–1336.
31. Welz, P.-S. and Benitah, S.A. Molecular connections between circadian clocks and aging. *J. Mol. Biol.* **2020**, *432*, 3661–3679.
32. Takahashi, J.S. Transcriptional architecture of the mammalian circadian clock. *Nat. Rev. Genet.* **2017**, *18*, 164–179.
33. Kondratov, R.V.; Chernov, M.V.; Kondratova, A.A.; Gorbacheva, V.Y.; Gudkov, A.V.; Antoch, M.P. BMAL1-dependent circadian oscillation of nuclear CLOCK: Posttranslational events induced by dimerization of transcriptional activators of the mammalian clock system. *Genes Dev.* **2003**, *17*, 1921–1932.
34. Farshadi, E.; van der Horst, G.T.J.; Chaves, I. Molecular links between the circadian clock and the cell cycle. *J. Mol. Biol.* **2020**, *432*, 3515–3524.
35. Qu, M. Molecular crosstalk between circadian clock and cancer and therapeutic implications. *Front. Nutr.* **2023**, *10*, 114.
36. Sancar, A.; Lindsey-Boltz, L.A.; Kang, T.-H.; Reardon, J.T.; Lee, J.H.; Ozturk, N. Circadian clock control of the cellular response to DNA damage. *FEBS Lett.* **2010**, *584*, 2618–2625.
37. Hoffman, A.E.; Zheng, T.; Ba, Y.; Zhu, Y. The circadian gene NPAS2, a putative tumor suppressor, is involved in DNA damage response. *Mol. Cancer Res.* **2008**, *6*, 1461–1468.
38. Olson, O.C.; Kang, Y.A.; Passequé, E. Normal hematopoiesis is a balancing act of self-renewal and regeneration. *Cold Spring Harb. Perspect. Med.* **2020**, *10*, a035519.
39. Maestroni, G. Circadian regulation of the immune-hematopoietic system. *Explor. Neurosci.* **2023**, *2*, 1–10.
40. Archer, S.N.; Laing, E.E.; Möller-Levet, C.S.; van der Veen, D.R.; Bucca, G.; Lazar, A.S.; Santhi, N.; Slak, A.; Kabiljo, R.; von Schantz, M.; Smith, C.P.; Dijk, D.-J. Mistimed sleep disrupts circadian regulation of the human transcriptome. *Proc. Natl. Acad. Sci. U.S.A.* **2014**, *111*, 682–691.
41. Allen, A.E. Circadian rhythms in the blind. *Curr. Opin. Behav. Sci.* **2019**, *30*, 1–6.
42. Zeng, Y.; Guo, Z.; Wu, M.; Chen, F.; Chen, L. Circadian rhythm regulates the function of immune cells and participates in the development of tumors. *Cell Death Discov.* **2024**, *10*, 199.
43. Scheiermann, C.; Kunisaki, Y.; Frenette, P.S. Circadian control of the immune system. *Nat. Rev. Immunol.* **2013**, *13*, 190–198.
44. Mohrin, M.; Bourke, E.; Alexander, D.; Warr, M.R.; Barry-Holson, K.; Le Beau, M.M.; Morrison, C.G.; Passequé, E. Hematopoietic stem cell quiescence promotes error-prone DNA repair and mutagenesis. *Cell Stem Cell* **2010**, *7*, 174–185.
45. Liu, Z.; Yu, K.; Zheng, J.; Lin, H.; Zhao, Q.; Zhang, X.; Feng, W.; Wang, L.; Xu, J.; Xie, D.; Zuo, Z.X.; Liu, Z.X.; Zheng, Q. Dysregulation, functional implications, and prognostic ability of the circadian clock across cancers. *Cancer Med.* **2019**, *8*, 1710–1720.
46. Wang, D.; Wang, F.; Zhang, H.; Chen, P.; Yang, M. Circadian clock protein Bmal1 accelerates acute myeloid leukemia by inhibiting ferroptosis through the EBF3/ALOX15 axis. *Cancer Sci.* **2023**, *114*, 3270–3282.

47. Taniguchi, H.; Fernández, A.F.; Setién, F.; Ropero, S.; Ballestar, E.; Villanueva, A.; Esteller, M. Epigenetic inactivation of the circadian clock gene BMAL1 in haematologic malignancies. *Cancer Res.* **2009**, *69*, 8447–8454.
48. Yang, M.Y.; Lin, P.M.; Hsiao, H.H.; Hsu, J.F.; Lin, H.Y.; Hsu, C.M.; Chen, I.Y.; Su, S.W.; Liu, Y.C.; Lin, S.F. Up-regulation of PER3 expression is correlated with better clinical outcome in acute leukemia. *Anticancer Res.* **2015**, *35*, 6615–6622.
49. Rahman, S.; Al-Hallaj, A.S.; Nedhi, A.; Gmati, G.; Abuelgasim, K.A.; Al Jama, H.; Trivilegio, T.; Mashour, A.; Al Askar, A.; Boudjelal, M. Differential expression of circadian genes in leukemia and a possible role for Sirt1 in restoring the circadian clock in chronic myeloid leukemia. *J. Circadian Rhythms* **2017**, *15*, 7.
50. Song, B.; Chen, Y.; Liu, Y.; Wan, C.; Zhang, L.; Zhang, W. NPAS2 regulates proliferation of acute myeloid leukemia cells via CDC25A-mediated cell cycle progression and apoptosis. *J. Cell. Biochem.* **2019**, *120*, 12375–12386.
51. Gery, S. and Koeffler, H.P. Per2 is a C/EBP target gene implicated in myeloid leukemia. *Integr. Cancer Ther.* **2009**, *8*, 317–320.
52. Miki, T.; Xu, Z.; Chen-Goodspeed, M.; Liu, M.; Van Oort-Jansen, A.; Rea, M.A.; Zhao, Z.; Lee, C.C.; Chang, K.S. PML regulates PER2 nuclear localization and circadian function. *EMBO J.* **2012**, *31*, 1427–1439.
53. Yang, X.; Wood, P.A.; Hrushesky, W.J.M. Mammalian TIMELESS is required for ATM-dependent CHK2 activation and G2/M checkpoint control. *J. Biol. Chem.* **2010**, *285*, 3030–3034.
54. Nicholson, R.; Menezes, A.C.; Azevedo, A.; Leckenby, A.; Davies, S.; Seedhouse, C.; Gilkes, A.; Knapper, S.; Tonks, A.; Darley, R.L. Protein kinase C epsilon overexpression is associated with poor patient outcomes in AML and promotes daunorubicin resistance through p-glycoprotein-mediated drug efflux. *Front. Oncol.* **2022**, *12*, 840046.
55. Mohy El-Din, A.M.M.; AlShaarawy, B.A.; Kandeel, E.Z.; AlDewi, D.M.; Refaat, L.A.A.; Arneth, B.; Sabit, H. Immunopathological Dysregulation in Acute Myeloid Leukemia: The Impact of T-bet, ROR $\gamma$ t, and FOXP3 on Disease Dynamics. *Cells* **2025**, *14*, 528.
56. Numata, A.; Kwok, H.S.; Kawasaki, A.; Li, J.; Zhou, Q.L.; Kerry, J.; Benoukraf, T.; Bararia, D.; Li, F.; Ballabio, E.; Tapia, M.; Deshpande, A.J.; Welner, R.S.; Delwel, R.; Yang, H.; Milne, T.A.; Taneja, R.; Tenen, D.G. The basic helix-loop-helix transcription factor SHARP1 is an oncogenic driver in MLL-AF6 acute myelogenous leukemia. *Nat. Commun.* **2018**, *9*, 222.
57. Trombly, D.J.; Whitfield, T.W.; Padmanabhan, S.; Gordon, J.A.R.; Lian, J.B.; van Wijnen, A.J.; Zaidi, S.K.; Stein, J.L.; Stein, G.S. Genome-wide co-occupancy of AML1-ETO and N-CoR defines the t(8;21) AML signature in leukemic cells. *BMC Genomics* **2015**, *16*, 309.
58. Jiang, W.; Zhao, S.; Jiang, X.; Zhang, E.; Hu, G.; Hu, B.; Zheng, P.; Xiao, J.; Lu, Z.; Lu, Y.; Ni, J.; Chen, C.; Wang, X.; Yang, L.; Wan, R.; Wan, R. The circadian clock gene Bmal1 acts as a potential anti-oncogene in pancreatic cancer by activating the p53 tumor suppressor pathway. *Cancer Lett.* **2016**, *371*, 314–325.
59. Dakup, P.P.; Porter, K.I.; Gajula, R.P.; Goel, P.N.; Cheng, Z.; Gaddameedhi, S. The circadian clock protects against ionizing radiation-induced cardiotoxicity. *FASEB J.* **2020**, *34*, 3347–3358.
60. Gotoh, T.; Vila, S.; Buhr, E.D.; Pyle, W.G.; Ciarleglio, C.M.; DeBruyne, J.P.; Shelton, J.L.; Colwell, C.S.; Cheng, H.Y.M. The circadian factor Period 2 modulates p53 stability and transcriptional activity in unstressed cells. *Mol. Biol. Cell* **2014**, *25*, 3081–3093.
61. Chen-Goodspeed, M. and Lee, C.C. Tumor suppression and circadian function. *J. Biol. Rhythms* **2007**, *22*, 291–298.
62. Im, J.S.; Jung, B.H.; Kim, S.E.; Lee, K.H.; Lee, J.K. Per3, a circadian gene, is required for Chk2 activation in human cells. *FEBS Lett.* **2010**, *584*, 4731–4734.
63. Zienolddiny, S.; Haugen, A.; Lie, J.A.; Kjuus, H.; Anmarkrud, K.H.; Kjørheim, K. Analysis of polymorphisms in the circadian-related genes and breast cancer risk in Norwegian nurses working night shifts. *Breast Cancer Res.* **2013**, *15*, R53.

64. Zhu, Y.; Stevens, R.G.; Hoffman, A.E.; Fitzgerald, L.M.; Kwon, E.M.; Ostrander, E.A.; Davis, S.; Zheng, T.; Stanford, J.L. Testing the circadian gene hypothesis in prostate cancer: A population-based case-control study. *Cancer Res.* **2009**, *69*, 9315–9322.
65. He, Q.; Qu, B.; Chen, Y.; Liu, L.; Zhao, C.; Li, Y.; Xu, X.; Luo, X.; Jin, F. The circadian clock gene BMAL1 increases radiosensitivity in nasopharyngeal carcinoma cell CNE2. *J. Radiat. Res. Appl. Sci.* **2024**, *17*, 100933.
66. Zhang, C.; Chen, L.; Sun, L.; Jin, H.; Ren, K.; Liu, S.; Qian, Y.; Li, S.; Li, F.; Zhu, C.; Zhao, Y.; Liu, H.; Liu, Y. BMAL1 collaborates with CLOCK to directly promote DNA double-strand break repair and tumor chemoresistance. *Oncogene* **2023**, *42*, 967–979.
67. Gery, S.; Komatsu, N.; Baldjyan, L.; Yu, A.; Koo, D.; Koefler, H.P. The circadian gene *Per1* plays an important role in cell growth and DNA damage control in human cancer cells. *Mol. Cell* **2006**, *22*, 375–382.
68. Xia, H.C.; Wang, F.; Li, Y.H.; Li, Z.K.; Cao, S.Z.; Li, C.Y.; Niu, Z.F. The circadian gene expression of *Per1* and *Per2* and their influence on radiotherapeutic sensitivity of glioma in vitro. *Future Neurol.* **2012**, *7*, 455–463.
69. Zhanfeng, N.; Yanhui, L.; Zhou, F.; Shaocai, H.; Guangxing, L.; Hechun, X. Circadian genes *Per1* and *Per2* increase radiosensitivity of glioma in vivo. *Oncotarget* **2015**, *6*, 9951–9960.
70. Shafi, A.A.; McNair, C.M.; McCann, J.J.; Alshalalfa, M.; Shostak, A.; Severson, T.M.; Zhu, Y.; Bergman, A.; Gordon, N.; Mandigo, A.C.; Chand, S.N.; Gallagher, P.; Dylgjeri, E.; Laufer, T.S.; Vasilevska, I.A.; Schiewer, M.J.; Brunner, M.; Feng, F.Y.; Zwart, W.; Knudsen, K.E. The circadian cryptochrome, *CRY1*, is a pro-tumorigenic factor that rhythmically modulates DNA repair. *Nat. Commun.* **2021**, *12*, 401.
71. Qin, F.; Liu, N.; Nie, J.; Shen, T.; Xu, Y.; Pan, S.; Pei, H.; Zhou, G. Circadian effects of ionizing radiation on reproductive function and clock genes expression in male mouse. *Environ. Health Prev. Med.* **2021**, *26*, 12.
72. Li, N.; Bruan, C.; Lin, S.H. Targeting REV-ERB/ROR $\alpha$ /IRF3 axis to enhance radiation-induced immune response in cancer radiotherapy. *Clin. Cancer Res.* **2025**, *31*, B006.
73. Rijo-Ferreira, F. and Takahashi, J.S. Genomics of circadian rhythms in health and disease. *Genome Med.* **2019**, *11*, 82.
74. Zhong, X.; Yu, J.; Frazier, K.; Weng, X.; Li, Y.; Cham, C.M.; Dolan, K.; Zhu, X.; Hubert, N.; Tao, Y.; Lin, F.; Martinez-Guryn, K.; Huang, Y.; Wang, T.; Liu, J.; He, C.; Chang, E.B.; Leone, V. Circadian clock regulation of hepatic lipid metabolism by modulation of m6A mRNA methylation. *Cell Rep.* **2018**, *25*, 1816–1828.e4.
75. Fustin, J.; Kojima, R.; Itoh, K.; Chang, H.; Ye, S.; Zhuang, B.; Oji, A.; Gibo, S.; Narasimamurthy, R.; Virshup, D.; Kurosawa, G.; Doi, M.; Manabe, I.; Ishihama, Y.; Ikawa, M.; Okamura, H. Two *Ckl1 $\delta$*  transcripts regulated by m6A methylation code for two antagonistic kinases in the control of the circadian clock. *Proc. Natl. Acad. Sci. U.S.A.* **2018**, *115*, 5980–5985.
76. Sang, L.; Wu, X.; Yan, T.; Naren, D.; Liu, X.; Zheng, X.; Zhang, N.; Wang, H.; Li, Y.; Gong, Y. The m6A RNA methyltransferase METTL3/METTL14 promotes leukemogenesis through the MDM2/p53 pathway in acute myeloid leukemia. *J. Cancer* **2022**, *13*, 1019–1030.
77. Su, R.; Dong, L.; Li, Y.; Gao, M.; Han, L.; Wunderlich, M.; Deng, X.; Li, H.; Huang, Y.; Gao, L.; Li, C.; Zhao, Z.; Robinson, S.; Tan, B.; Qing, Y.; Qin, X.; Prince, E.; Xie, J.; Qin, H.; Li, W.; Shen, C.; Sun, J.; Kulkarni, P.; Weng, H.; Huang, H.; Chen, Z.; Zhang, B.; Wu, X.; Olsen, M.J.; Müschen, M.; Marcucci, G.; Salgia, R.; Li, L.; Fathi, A.T.; Li, Z.; Mulloy, J.C.; Wei, M.; Horne, D.; Chen, J. Targeting FTO suppresses cancer stem cell maintenance and immune evasion. *Cancer Cell* **2020**, *38*, 79–96.e11.
78. Shen, C.; Sheng, Y.; Zhu, A.C.; Robinson, S.; Jiang, X.; Dong, L.; Chen, H.; Su, R.; Yin, Z.; Li, W.; Deng, X.; Chen, Y.; Hu, Y.-C.; Weng, H.; Huang, H.; Prince, E.; Cogle, C.R.; Sun, M.; Zhang, B.; Chen, C.-W.; Marcucci, G.; He, C.; Qian, Z. RNA demethylase ALKBH5 selectively promotes tumorigenesis and cancer stem cell self-renewal in acute myeloid leukemia. *Cell Stem Cell* **2020**, *27*, 64–80.e9.

79. Cruz-Garcia, L.; Davies, P.; Goriacha, V.; Najim, M.; Polozov, S.; Polozova, M.; Badie, C. Dynamic modulation of N6-methyladenosine by ionizing radiation in human cells. *Biochem. Biophys. Rep.* **2026**, *45*, 102528.
80. Zhang, S.; Dong, J.; Li, Y.; Xiao, H.; Shang, Y.; Wang, B.; Chen, Z.; Zhang, M.; Fan, S.; Cui, M. Gamma-irradiation fluctuates the mRNA N6-methyladenosine (m6A) spectrum of bone marrow in hematopoietic injury. *Environ. Pollut.* **2021**, *285*, 117509.
81. Cheng, Y.; Shang, Y.; Zhang, S.; Fan, S. The interplay between RNA m6A modification and radiation biology of cancerous and non-cancerous tissues: a narrative review. *Cancer Biol. Med.* **2025**, *21*, 1120–1140.
82. Asher, G.; Gatfield, D.; Stratmann, M.; Reinke, H.; Dibner, C.; Kreppel, F.; Mostoslavsky, R.; Alt, F.W.; Schibler, U. SIRT1 regulates circadian clock gene expression through PER2 deacetylation. *Cell* **2008**, *134*, 317–328.
83. Dan, L.; Klimenkova, O.; Klimiankou, M.; Klusman, J.-H.; van den Heuvel-Eibrink, M.M.; Reinhardt, D.; Welte, K.; Skokowa, J. The role of sirtuin 2 activation by nicotinamide phosphoribosyltransferase in the aberrant proliferation and survival of myeloid leukemia cells. *Haematologica* **2012**, *97*, 553–562.
84. Li, L.; Osdal, T.; Ho, Y.; Chun, S.; McDonald, T.; Agarwal, P.; Lin, A.; Chu, S.; Qi, J.; Li, L.; Hsieh, Y.-T.; Dos Santos, C.; Yuan, H.; Ha, T.-Q.; Popa, M.; Hovland, R.; Bruserud, Ø.; Gjertsen, B.T.; Bhatia, R. SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cells. *Cell Stem Cell* **2014**, *15*, 431–446.
85. Hanahan, D. Hallmarks of cancer – Then and now, and beyond. *Cell* **2026**, in press.
86. Fortin, B.M.; Mahieu, A.L.; Fellows, R.C.; Kang, Y.; Lewis, A.N.; Ead, A.S.; Lamia, K.A.; Cao, Y.; Pannunzio, N.R.; Masri, S. The diverse roles of the circadian clock in cancer. *Nat. Cancer* **2025**, *6*, 753–767.
87. Zhang, F.; Chen, M.; Hu, S.; Pang, K.; Jin, W. Circadian rhythms in cancer: mechanistic insights, chronotherapeutic strategies, and translational challenges. *Ann. Surg. Oncol.* **2026**, in press.
88. Quan, X.; Li, N.; Huang, J.; Duan, Y. CLOCK-mediated acetylation of NF- $\kappa$ B p65 drives immune evasion in breast cancer. *Biol. Direct* **2025**, *20*, 112.
89. Fortin, B.M.; Pfeiffer, S.M.; Insua-Rodríguez, J.; Alshetaiwi, H.; Moshensky, A.; Song, W.A.; Mahieu, A.L.; Chun, S.K.; Lewis, A.N.; Hsu, A.; Adam, I.; Eng, O.S.; Pannunzio, N.R.; Seldin, M.M.; Marazzi, I.; Marangoni, F.; Lawson, D.A.; Kessenbrock, K.; Masri, S. Circadian control of tumor immunosuppression affects efficacy of immune checkpoint blockade. *Nat. Immunol.* **2024**, *25*, 1257–1269.
90. Bizymi, N.; Bjelica, S.; Kittang, A.O.; Mojsilovic, S.; Velegraki, M.; Pontikoglou, C.; Roussel, M.; Ersvør, E.; Santibañez, J.F.; Lipoldová, M.; Papadaki, H.A. Myeloid-derived suppressor cells in hematologic diseases: promising biomarkers and treatment targets. *HemaSphere* **2019**, *3*, e168.
91. Khan, S.; Yong, V.W.; Xue, M. Circadian disruption in mice through chronic jet lag-like conditions modulates molecular profiles of cancer in nucleus accumbens and prefrontal cortex. *Carcinogenesis* **2021**, *42*, 864–873.
92. Inokawa, H.; Umemura, Y.; Shimba, A.; Kawakami, E.; Koike, N.; Tsuchiya, Y.; Ohashi, M.; Minami, Y.; Cui, G.; Asahi, T.; Ono, R.; Sasawaki, Y.; Konishi, E.; Yoo, S.H.; Chen, Z.; Teramukai, S.; Ikuta, K.; Yagita, K. Chronic circadian misalignment accelerates immune senescence and abbreviates lifespan in mice. *Sci. Rep.* **2020**, *10*, 2569.
93. Boivin, D.B.; Boudreau, P.; Kosmadopoulos, A. Disturbance of the circadian system in shift work and its health impact. *J. Biol. Rhythms* **2022**, *37*, 3–28.
94. Ablasser, A.; Chen, Z.J. cGAS in action: Expanding roles in immunity and inflammation. *Sci.* **2019**, *363*, eaat8657.
95. Basit, A.; Cho, M.-G.; Kim, E.-Y.; Kwon, D.; Kang, S.-J.; Lee, J.-H. The cGAS/STING/TBK1/IRF3 innate immunity pathway maintains chromosomal stability through regulation of p21 levels. *Exp. Mol. Med.* **2020**, *52*, 643–657.

96. Ngwa, W.; Irabor, O.C.; Schoenfeld, J.D.; Hesser, J.; Demaria, S.; Formenti, S.C. Using immunotherapy to boost the abscopal effect. *Nat. Rev. Cancer* **2018**, *18*, 313–322.
97. Constanzo, J.; Faget, J.; Ursino, C.; Badie, C.; Pouget, J.-P. Radiation-induced immunity and toxicities: the versatility of the cGAS-STING pathway. *Front. Immunol.* **2021**, *12*, 680503.
98. Chen, Q.; Hong, Y.; Chen, W.; Lin, F.; Zeng, J.; Huang, Y.; Zhang, L.; Yao, J.; Xu, B. Prognostic implications of cGAS and STING gene expression in acute myeloid leukemia. *Exp. Biol. Med.* **2024**, *249*, 10108.
99. Ma, Y.; Wang, D.; Feng, L.; Chang, M.; Li, M.; Meng, G.; Wu, Y.; Lu, F.; Sun, T.; Ji, C.; Ye, J. Gene polymorphisms of molecules of the cGAS-STING signalling pathway are associated with AML in Chinese patients. *Holist. Integr. Oncol.* **2024**, *3*, 15.
100. Zhang, C.; Ye, S.; Ni, J.; Cai, T.; Liu, Y.; Huang, D.; Mai, H.; Chen, Q.; He, J.; Zhang, X.; Zeng, Y.; Li, J.; Cui, J. STING signaling remodels the tumor microenvironment by antagonizing myeloid-derived suppressor cell expansion. *Cell Death Differ.* **2019**, *26*, 2314–2328.

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.